# Angiocrine Bioscience

Source: https://onco.cc/companies/angiocrine-bioscience/  
OnCo record `angiocrine-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Angiocrine is a San Diego company that infuses engineered blood-vessel lining cells to help patients recover from the high-dose chemotherapy given before stem cell transplants for lymphoma and myeloma.

## Summary

Angiocrine Bioscience, founded in 2012 in San Diego from Weill Cornell research, develops AB-205, an engineered endothelial cell product given after high-dose chemotherapy and autologous stem cell transplant to reduce severe regimen-related toxicities such as mucositis. It leads a phase 3 trial in lymphoma patients registered on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Angiocrine Bioscience, Inc.; Angiocrine
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: cell-therapy
- Website: http://angiocrinebioscience.com

## Sources

- Official website: http://angiocrinebioscience.com
- ClinicalTrials.gov: trials led by Angiocrine Bioscience, Inc.: https://clinicaltrials.gov/search?lead=Angiocrine%20Bioscience%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q36875394

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/angiocrine-bioscience.json